Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands

Michelle Maria Aleida Kip, M. Bosch, K. Fischer, R.Y.J. Tamminga, I. Lepage-Nefkens

    Research output: Contribution to conferencePaper

    Original languageEnglish
    Publication statusPublished - 8 Nov 2014
    EventISPOR 17th Annual European Congress 2014: New challenges for improving European health care - Amsterdam RAI, Amsterdam, Netherlands
    Duration: 8 Nov 201412 Nov 2014

    Conference

    ConferenceISPOR 17th Annual European Congress 2014
    Abbreviated titleISPOR
    CountryNetherlands
    CityAmsterdam
    Period8/11/1412/11/14

    Keywords

    • METIS-306280
    • IR-92434

    Cite this

    Kip, M. M. A., Bosch, M., Fischer, K., Tamminga, R. Y. J., & Lepage-Nefkens, I. (2014). Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands. Paper presented at ISPOR 17th Annual European Congress 2014, Amsterdam, Netherlands.